Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 10, 2023

SELL
$0.07 - $0.23 $612 - $2,011
-8,744 Reduced 98.98%
90 $0
Q3 2022

Nov 10, 2022

BUY
$0.25 - $2.24 $2,208 - $19,788
8,834 New
8,834 $3,000
Q2 2022

Aug 15, 2022

SELL
$1.72 - $2.51 $8,280 - $12,083
-4,814 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$1.72 - $2.47 $6,179 - $8,874
3,593 Added 294.27%
4,814 $12,000
Q4 2021

Feb 14, 2022

BUY
$1.69 - $2.31 $2,063 - $2,820
1,221 New
1,221 $3,000
Q3 2021

Nov 15, 2021

SELL
$1.22 - $2.2 $15,740 - $28,384
-12,902 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$2.06 - $2.67 $12,156 - $15,755
-5,901 Reduced 31.38%
12,902 $29,000
Q1 2021

May 17, 2021

BUY
$2.49 - $6.23 $46,650 - $116,719
18,735 Added 27551.47%
18,803 $48,000
Q4 2020

Feb 16, 2021

SELL
$3.48 - $6.47 $34,904 - $64,894
-10,030 Reduced 99.33%
68 $0
Q3 2020

Nov 16, 2020

BUY
$3.16 - $4.36 $27,615 - $38,102
8,739 Added 643.05%
10,098 $41,000
Q2 2020

Aug 13, 2020

SELL
$1.87 - $3.84 $6,627 - $13,608
-3,544 Reduced 72.28%
1,359 $5,000
Q1 2020

May 15, 2020

SELL
$1.58 - $4.06 $1,559 - $4,007
-987 Reduced 16.76%
4,903 $9,000
Q4 2019

Feb 07, 2020

BUY
$2.13 - $3.83 $12,545 - $22,558
5,890 New
5,890 $23,000
Q3 2019

Nov 05, 2019

SELL
$2.12 - $2.86 $1,785 - $2,408
-842 Closed
0 $0
Q2 2019

Aug 13, 2019

SELL
$2.35 - $3.09 $10,678 - $14,040
-4,544 Reduced 84.37%
842 $2,000
Q1 2019

May 14, 2019

SELL
$1.8 - $2.97 $9,819 - $16,201
-5,455 Reduced 50.32%
5,386 $14,000
Q4 2018

Feb 14, 2019

BUY
$1.51 - $2.93 $15,409 - $29,900
10,205 Added 1604.56%
10,841 $20,000
Q3 2018

Nov 13, 2018

SELL
$2.6 - $3.95 $22,963 - $34,886
-8,832 Reduced 93.28%
636 $2,000
Q2 2018

Aug 15, 2018

BUY
$3.7 - $4.75 $21,989 - $28,229
5,943 Added 168.6%
9,468 $37,000
Q1 2018

May 15, 2018

BUY
$4.05 - $6.1 $14,276 - $21,502
3,525 New
3,525 $15,000
Q4 2017

Feb 09, 2018

SELL
$2.8 - $5.55 $1,120 - $2,220
-400 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$3.2 - $20.8 $1,280 - $8,320
400
400 $1,000

About OTONOMY, INC.


  • Ticker OTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,990,400
  • Description
  • Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...
More about OTIC
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.